Thrombosis Research
Volume 118, Issue 4 , Pages 471-477 , 2006

Aspirin overprescription in primary cardiovascular prevention

  • Costantina Manes

      Affiliations

    • Institute of Cardiology, “G. d'Annunzio” University-Chieti, Italy
    • Center of Excellence on Aging, “Gabriele d'Annunzio” University Foundation-Chieti, Italy
    • ,
  • Luciano Giacci

      Affiliations

    • Società Italiana di Medicina Generale, Sezione di Chieti, Chieti, Italy
    • ,
  • Adolfo Sciartilli

      Affiliations

    • Institute of Cardiology, “G. d'Annunzio” University-Chieti, Italy
    • ,
  • Alberto D'Alleva

      Affiliations

    • Institute of Cardiology, “G. d'Annunzio” University-Chieti, Italy
    • ,
  • Raffaele De Caterina

      Affiliations

    • Institute of Cardiology, “G. d'Annunzio” University-Chieti, Italy
    • Center of Excellence on Aging, “Gabriele d'Annunzio” University Foundation-Chieti, Italy
    • CNR Institute of Clinical Physiology, Pisa, Italy
    • Corresponding Author InformationCorresponding author. Institute of Cardiology, “G. d'Annunzio” University-Chieti, c/o Ospedale S. Camillo de Lellis-Via Forlanini, 50 66100 Chieti, Italy. Tel.: +39 871 41512; fax: +39 871 402817.

Received 8 June 2005 ,Revised 28 September 2005 ,Accepted 28 September 2005.

References 

  1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81–106
  2. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86
  3. Boissel J. Individualizing aspirin therapy for prevention of cardiovascular events. JAMA. 1998;280:1949–1950
  4. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA. 1998;280:1930–1935
  5. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:234S–264S
  6. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 1998;351:233–241
  7. Hansson L, Zanchetti A, Curruthers SG, et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755–1762
  8. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1997;96:2751–2753
  9. Lauer MS. Clinical practice. Aspirin for primary prevention of coronary events. N Engl J Med. 2002;346:1468–1474
  10. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293–1304
  11. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart. 2001;85:265–271
  12. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Circulation. 2002;106:388–391
  13. U.S. Preventive Services Task Force . Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002;136:157–160
  14. De Caterina R. Low-dose aspirin in the primary prevention of cardiovascular disease: how to balance the benefits and the risks. Ital Heart J. 2003;4:228–231
  15. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Eur Heart J. 1998;19:1434–1503
  16. Carta Italiana del Rischio Cardiovascolare. Pubblicazioni Centro per la Lotta contro l'Infarto ed. Roma: Pubblicazioni Centro per la Lotta contro l'Infarto; 2001.
  17. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136:161–172
  18. Second Joint Task Force of European and other Societies on coronary prevention. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Eur Heart J. 1998;19:1434–1503
  19. Becker RC, Burns M, Gore JM, Lambrew C, French W, Rogers WJ. Early and pre-discharge aspirin administration among patients with acute myocardial infarction: current clinical practice and trends in the United States. J Thromb Thrombolysis. 2000;9:207–215
  20. Califf RM, DeLong ER, Ostbye T, Muhlbaier LH, Chen A, LaPointe NA, et al. Underuse of aspirin in a referral population with documented coronary artery disease. Am J Cardiol. 2002;89:653–661
  21. Klinke JA, Johnson JA, Guirguis LM, Toth EL, Lee TK, Lewanczuk RZ, et al. Underuse of aspirin in type 2 diabetes mellitus: prevalence and correlates of therapy in rural Canada. Clin Ther. 2004;26:439–446
  22. Strandberg T, Pitkala K, Tilvis R. Benefits of optimising drug treatment in home-dwelling elderly patients with coronary artery disease. Drugs Aging. 2003;20:585–595
  23. Alexander JH, Harrington RA, Tuttle RH, Berdan LG, Lincoff AM, Deckers JW, et al. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. Am J Cardiol. 1999;83:1147–1151
  24. Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham study. Am Heart J. 1985;110:1100–1107
  25. Pyorala K. Assessment of coronary heart disease risk in populations with different levels of risk. Eur Heart J. 2000;21:348–350
  26. D'Agostino RB, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286:180–187
  27. Menotti A, Puddu PE, Lanti M. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J. 2000;21:365–370
  28. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003
  29. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet. 2001;357:995–1001
  30. Casella G, Savonitto S, Chiarella F, Gonzini L, Di Chiara A, Bolognese L, et al. Clinical characteristics and outcome of diabetic patients with acute myocardial infarction. Data from the BLITZ-1 study. Ital Heart J. 2005;6:374–383

PII: S0049-3848(05)00417-2

doi: 10.1016/j.thromres.2005.09.013

Thrombosis Research
Volume 118, Issue 4 , Pages 471-477 , 2006

Article Tools